Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM treatment survey

Journal of Rheumatology

Volumn 37, Issue 9, 2010, Pages 1953-1961

  Stringer, Elizabeth ^a   Bohnsack, John ^b   Bowyer, Suzanne L ^c   Griffin, Thomas A ^d   Huber, Adam M ^a   Lang, Bianca ^a   Lindsley, Carol B ^e   Ota, Sylvia ^f   Pilkington, Clarissa ^g   Reed, Ann M ^h   Scuccimarri, Rosie ⁱ   Feldman, Brian M ^f  

^a IWK HEALTH CENTRE   (Canada)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

^g GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^h MAYO CLINIC   (United States)

ⁱ MONTREAL CHILDREN S HOSPITAL   (Canada)

Author keywords

Juvenile dermatomyositis; Myositis; Pediatric rheumatology; Treatment

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE;

ARTICLE; CHILDHOOD ARTHRITIS AND RHEUMATOLOGY RESEARCH ALLIANCE; DERMATOMYOSITIS; DISEASE SEVERITY; DRUG INDICATION; HUMAN; JUVENILE DERMATOMYOSITIS; NORTH AMERICA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADRENAL CORTEX HORMONES; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CYCLOPHOSPHAMIDE; DERMATOMYOSITIS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; METHOTREXATE; RESEARCH DESIGN; THERAPEUTIC HUMAN EXPERIMENTATION; TREATMENT OUTCOME;

EID: 77956453825     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090953     Document Type: Article

References (43)

1. Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, et al. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003;49:300-5.
2. Bitnum S, Daeschner CW Jr, Travis LB, Dodge WF, Hopps HC. Dermatomyositis. J Pediatr 1964;64:101-31.
3. Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000;43:541-9.
4. Christen-Zaech S, Seshadri R, Sundberg J, Paller AS, Pachman LM. Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. Arthritis Rheum 2008;58:571-6.
5. Stringer E, Singh-Grewal D, Feldman BM. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum 2008;58:3585-92.
6. Miller LC, Michael AF, Kim Y. Childhood dermatomyositis. Clinical course and long-term follow-up. Clin Pediatr 1987;26:561-6.
7. Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 1983;103:882-8.
8. Ramanan AV, Campbell-Webster N, Ota S, Parker S, Tran D, Tyrrell PN, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 2005;52:3570-8.
9. Rider LG. The heterogeneity of juvenile myositis. Autoimmun Rev 2007;6:241-7.
10. Sallum AM, Kiss MH, Sachetti S, Resende MB, Moutinho KC, Carvalho MS, et al. Juvenile dermatomyositis: clinical, laboratorial, histological, therapeutical and evolutive parameters of 35 patients. Arq Neuropsiquiatr 2002;60:889-99.
11. Taieb A, Guichard C, Salamon R, Maleville J. Prognosis in juvenile dermatopolymyositis: a cooperative retrospective study of 70 cases. Pediatr Dermatol 1985;2:275-81.
12. Seshadri R, Feldman BM, Ilowite N, Cawkwell G, Pachman LM. The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum 2008;59:989-95.
13. Klein-Gitelman MS, Waters T, Pachman LM. The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis. Arthritis Care Res 2000;13:360-8.
14. Lang BA, Laxer RM, Murphy G, Silverman ED, Roifman CM. Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 1991;91:169-72.
15. Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 2000;27:2498-503.
16. Sansome A, Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis - four year review of nine cases. Arch Dis Child 1995;72:25-8.
17. Olson NY, Lindsley CB. Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol 1989;16:1545-7.
18. Zeller V, Cohen P, Prieur AM, Guillevin L. Cyclosporin A therapy in refractory juvenile dermatomyositis. Experience and longterm followup of 6 cases. J Rheumatol 1996;23:1424-7.
19. Reiff A, Rawlings DJ, Shaham B, Franke E, Richardson L, Szer IS, et al. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol 1997;24:2436-43.
20. Edge JC, Outland JD, Dempsey JR, Callen JP. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 2006;142:65-9.
21. Yamada A, Ohshima Y, Omata N, Yasutomi M, Mayumi M. Steroid-sparing effect of tacrolimus in a patient with juvenile dermatomyositis presenting poor bioavailability of cyclosporine A. Eur J Pediatr 2004;163:561-2.
22. Riley P, Maillard SM, Wedderburn LR, Woo P, Murray KJ, Pilkington CA. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology 2004;43:491-6.
23. Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 2007;56:3107-11.
24. Dillman DA. Mail and internet surveys: The tailored design method. 2nd ed. New York: John Wiley and Sons Inc.; 2000.
25. Miller LC, Sisson BA, Tucker LB, DeNardo BA, Schaller JG. Methotrexate treatment of recalcitrant childhood dermatomyositis. Arthritis Rheum 1992;35:1143-9.
26. Rouster-Stevens KA, Gursahaney A, Ngai K-L, Daru JA, Pachman LM. Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum 2008;59:222-6.
27. Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002;47:505-11.
28. Callen AM, Pachman L, Hayford J, Chung A, Ramsey-Goldman R. Intermittent high-dose intravenous methylprednisolone (IV pulse) therapy prevents calcinosis and shortens disease course in juvenile dermatomyositis (JDMS) [abstract]. Arthritis Rheum 1994;37 Suppl:R10.
29. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993-2000.
30. Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senecal JL, Cividino A, et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 1998;7:80-5.
31. Pope JE, Hong P, Koehler BE. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists. J Rheumatol 2002;29:255-60.
32. Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin North Am 1994;20:243-63.
33. Woo TY, Callen JP, Voorhees JJ, Bickers DR, Hanno R, Hawkins C. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol 1984;10:592-600.
34. Bloom BJ, Tucker LB, Klein-Gitelman M, Miller LC, Schaller JG. Worsening of the rash of juvenile dermatomyositis with hydroxychloroquine therapy. J Rheumatol 1994;21:2171-2.
35. Pelle MT, Callen JP. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol 2002;138:1231-3.
36. Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008;67:1670-7.
37. Hengstman GJ, van den Hoogen FH, van Engelen BG. Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up. Eur Neurol 2004;52:61-3.
38. Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology 2008;47:877-80.
39. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005;52:601-7.
40. Brown VE, Pilkington CA, Feldman BM, Davidson JE. An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology 2006;45:990-3.
41. Maillard SM, Jones R, Owens CM, Pilkington C, Woo PM, Wedderburn LR, et al. Quantitative assessments of the effects of a single exercise session on muscles in juvenile dermatomyositis. Arthritis Rheum 2005;53:558-64.
42. Takken T, van der Net J, Engelbert RH, Pater S, Helders PJ. Responsiveness of exercise parameters in children with inflammatory myositis. Arthritis Rheum 2008;59:59-64.
43. Pediatric Rheumatology INternational Trials Organization. Juvenile Dermatomyositis Trial. 2009. [Internet. Accessed May 7, 2010.] Available from: http://www.printo.it/project-ongoing-detail.asp?ProjectID=14